



Claims

1. An antiepileptic agent comprising a xanthine derivative represented by the formula (I):



5 [wherein R¹, R² and R³ are the same or different and each represents a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl;

R⁴ represents cycloalkyl, -(CH₂)_n-R⁵ (wherein R⁵ represents substituted or unsubstituted aryl or substituted or unsubstituted heterocyclic group and n represents an integer of 0 to 4) or the formula (II):




(wherein Y¹ and Y² are the same or different and each represents a hydrogen atom, halogen or lower alkyl and Z represents 15 substituted or unsubstituted aryl or substituted or unsubstituted heterocyclic group); and

X¹ and X² are the same or different and each represents an oxygen atom or a sulfur atom] or a pharmaceutically acceptable salt thereof as an active ingredient.

20 2. The antiepileptic agent according to claim 1, wherein

X^1 and X^2 are oxygen atoms.


3. The antiepileptic agent according to claim 1 or 2, wherein R^4 is the formula (II):



5 (wherein Y^1 , Y^2 and Z have the same meanings as defined above, respectively).


4. The antiepileptic agent according to claim 3, wherein Y^1 and Y^2 are hydrogen atoms.

5. The antiepileptic agent according to claim 3 or 4, 10 wherein Z is substituted or unsubstituted aryl or the formula (III):




(wherein R^6 represents a hydrogen atom, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino; and m represents an 15 integer of 1 to 3).

6. A method for treating epilepsy, which comprises administering an effective amount of a xanthine derivative represented by the formula (I):



[wherein R¹, R² and R³ are the same or different and each represents a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl;


5 R⁴ represents cycloalkyl, -(CH₂)_n-R⁵ (wherein R⁵ is substituted or unsubstituted aryl or substituted or unsubstituted heterocyclic group and n represents an integer of 0 to 4) or the formula (II):



10 (wherein Y¹ and Y² are the same or different and each represents a hydrogen atom, halogen or lower alkyl and Z represents substituted or unsubstituted aryl or substituted or unsubstituted heterocyclic group); and


15 X¹ and X² are the same or different and each represents an oxygen atom or a sulfur atom] or a pharmaceutically acceptable salt thereof.

7. Use of a xanthine derivative represented by the formula (I):



[wherein R¹, R² and R³ are the same or different and each represents a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl;

5 R⁴ represents cycloalkyl, -(CH₂)_n-R⁵ (wherein R⁵ represents substituted or unsubstituted aryl or substituted or unsubstituted heterocyclic group and n represents an integer of 0 to 4) or the formula (II):



10 (wherein Y¹ and Y² are the same or different and each represents hydrogen atom, halogen or lower alkyl and Z represents substituted or unsubstituted aryl or substituted or unsubstituted heterocyclic group); and

15 X¹ and X² are the same or different and each represents an oxygen atom or a sulfur atom] or a pharmaceutically acceptable salt thereof, for the manufacture of an antiepileptic agent.